The treatment of pediatric chronic myelogenous leukemia in the imatinib era
Childhood chronic myelogenous leukemia (CML) is a rare hematologic disease, with limited literature on the methods of treatment. Previously, allogeneic hematopoietic stem cell transplantation (HSCT) was considered the only curative treatment for this disease. Treatment with imatinib, a selective inh...
Main Authors: | Jae Wook Lee, Nack Gyun Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Pediatric Society
2011-03-01
|
Series: | Korean Journal of Pediatrics |
Subjects: | |
Online Access: | http://kjp.or.kr/upload/pdf/kjped-54-111.pdf |
Similar Items
-
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01) -
TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01) -
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
by: Emole J, et al.
Published: (2016-02-01) -
Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01) -
Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)